Pekkolay, ZaferKilinc, FarukSoylu, HikmetBalsak, BelmaGuven, MehmetTuzcu, Sadiye AltunKara, Ali Veysel2024-04-242024-04-2420192587-0823https://doi.org/10.5606/tftrd.2019.2718https://search.trdizin.gov.tr/yayin/detay/382829https://hdl.handle.net/11468/2028039th Turkey Congress of Endocrinology and Metabolic Diseases -- MAY 03-07, 2017 -- Antalya, TURKEYHypoparathyroidism usually responds to oral active vitamin D and calcium, but, although rare, some patients do not respond to this treatment. A 47-year-old Caucasian female presented to our medical unit with classical oral treatment-resistant hypocalcemia after thyroidectomy. Teriparatide was infused through the insulin pump with dosage set to 1 unit which equals to 2.5 mu g of teriparatide. In conclusion, intermittent subcutaneous infusion of teriparatide using an insulin pump is a safe and effective treatment modality to ensure normocalcemic conditions in patients with classical treatment-resistant hypoparathyroidism.eninfo:eu-repo/semantics/openAccessHypoparathyroidismPump InfusionTeriparatideConference Object652198201WOS:0004767025000133828293145356310.5606/tftrd.2019.2718Q4